-
公开(公告)号：US20240166724A1
公开(公告)日：2024-05-23
申请号：US18548545
申请日：2022-03-02
Applicant: GRIFOLS WORLDWIDE OPERATIONS LIMITED
Inventor： Raquel HORRILLO SAURA , Montserrat COSTA RIEROLA , Francesc Xavier XIFRO COLLSAMATA , Sandra CAMPRUBI GIMENEZ
Abstract: Alpha-1-antitrypsin can be used as a therapeutic agent in patients that have suffered neural cell injury arising from traumatic or non-traumatic causes such as an ischemic stroke, cerebral hypoxia or spinal cord injuries. Alpha-1-antitrypsin can also be used in the treatment of neuropathic pain and the promotion of spinal cord revascularization following injury. Compositions including alpha-1 antitrypsin can be administered parenterally or by inhalation to the patients as part of a dosing regimen.
-
公开(公告)号：US20240165077A1
公开(公告)日：2024-05-23
申请号：US18280565
申请日：2022-03-17
Applicant: Cognition Therapeutics, Inc.
Inventor： Anthony CAGGIANO , Susan M. CATALANO , Mary HAMBY , Nicholas IZZO , Gary C. LOOK , Gilbert M. RISHTON
IPC: A61K31/4035 , A61K31/445 , A61K31/453 , A61K31/496 , A61P25/28
CPC classification number: A61K31/4035 , A61K31/445 , A61K31/453 , A61K31/496 , A61P25/28
Abstract: The present disclosure relates to methods of treating neurological diseases, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein. The present disclosure relates to the methods of treating Parkinson's disease and Dementia with Lew Bodies, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound or pharmaceutical composition according to any embodiment described herein.
-
公开(公告)号：US11987580B2
公开(公告)日：2024-05-21
申请号：US17559488
申请日：2021-12-22
Applicant: Alkermes, Inc.
Inventor： Nathan Oliver Fuller , John A. Lowe, III
IPC: A61K31/519 , A61K31/437 , A61P25/28 , C07D471/04 , C07D487/04
CPC classification number: C07D471/04 , A61K31/437 , A61K31/519 , A61P25/28 , C07D487/04
Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2). The compounds are bicyclic inhibitors of histone deacetylase, useful for treating neurological disorders, memory or cognitive function disorders or impairments, extinction learning disorders, fungal diseases or infections, inflammatory diseases, hematological diseases, neoplastic diseases, psychiatric disorders, and memory loss.
-
公开(公告)号：US11986499B2
公开(公告)日：2024-05-21
申请号：US17455173
申请日：2021-11-16
Applicant: ILiAD Biotechnologies, LLC
Inventor： Keith Rubin , Steven Glazer , Marina Lynch , Kingston Mills
Abstract: Administering a live, attenuated Bordetella pertussis-based vaccine to a subject at risk for developing a neurodegenerative disease featuring Aβ brain plaques can prevent or reduce the amount of Aβ brain plaques that would have developed in the subject without such treatment.
-
公开(公告)号：US11981711B2
公开(公告)日：2024-05-14
申请号：US17137875
申请日：2020-12-30
Applicant: The Cleveland Clinic Foundation
Inventor： Yu-Shang Lee , Ching-Yi Lin
IPC: A61K38/00 , A61K9/00 , A61K31/727 , A61K38/17 , A61K38/18 , A61K49/00 , A61P25/00 , A61P25/28 , C07K14/00 , C07K14/47 , C07K14/48 , C07K19/00 , A61K31/737 , A61K38/16 , A61K38/39 , A61K39/00 , A61K47/42 , A61K47/64 , A61K48/00 , A61K49/14 , A61L27/22 , A61P17/02 , G01N33/50 , G01N33/68
CPC classification number: C07K14/4703 , A61K9/0019 , A61K31/727 , A61P25/00 , A61P25/28 , C07K19/00 , A61K31/737 , A61K38/00 , A61K38/16 , A61K38/1709 , A61K38/39 , A61K2039/55516 , A61K2039/6031 , A61K47/42 , A61K47/64 , A61K47/645 , A61K48/005 , A61K49/0056 , A61K49/14 , A61K2121/00 , A61K2300/00 , A61L27/22 , A61L2300/236 , A61L2300/252 , A61L2430/32 , A61P17/02 , C07K2319/03 , C07K2319/70 , C07K2319/95 , G01N33/5058 , G01N33/68
Abstract: Provided herein are compositions, systems, kits, and methods for treating nervous system injuries caused by trauma or neurodegeneration or aging in a subject by administering a CSPG or SOCS3 reduction peptide (CRP and SRP respectively), or a nucleic acid sequence encoding the CRP or SRP, wherein both the CRP and SRP comprise a cell membrane penetrating domain, and a lysosome targeting domain, and the CRP further comprises a chondroitin sulfate proteoglycan (CSPG) binding domain, and the SRP further comprises a suppressor of cytokine signaling-3 (SOCS3) binding domain.
-
Patent Agency Ranking
公开(公告)号：US11981652B2
公开(公告)日：2024-05-14
申请号：US17042726
申请日：2019-03-28
Applicant: Emory University
Inventor： Dennis Liotta , Stephen Traynelis , Yao Jing
IPC: C07D401/04 , A61K31/415 , A61K31/4155 , A61K31/4709 , A61K31/497 , A61K45/06 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/28 , C07D231/06 , C07D401/14 , C07D405/04 , C07D409/04 , C07D409/14
CPC classification number: C07D401/04 , A61K31/415 , A61K31/4155 , A61K31/4709 , A61K31/497 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/28 , C07D231/06 , C07D405/04 , C07D409/04 , C07D409/14 , A61K45/06 , C07D401/14 , A61K31/4709 , A61K2300/00 , A61K31/4155 , A61K2300/00 , A61K31/415 , A61K2300/00 , A61K31/497 , A61K2300/00
Abstract: A compound according to Formula (I) or salts or prodrugs thereof and pharmaceutical formulations comprising the compound are provided herein for the treatment of neurological disorders. The disorders may include providing neuroprotection, preventing neurodegeneration, treating neuropathic pain or treating schizophrenia, psychoses or depression. Furthermore, the compounds may be used in combination with another active ingredient.
-
公开(公告)号：US20240150756A1
公开(公告)日：2024-05-09
申请号：US18305195
申请日：2023-04-21
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： Maria David Frank-Kamenetsky , Hailin Yang , Aaron Jay Morris , Chandra Vargeese , Christopher J. Francis
IPC: C12N15/113 , A61P25/28 , C12N15/115
CPC classification number: C12N15/113 , A61P25/28 , C12N15/115 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346
Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.
-
公开(公告)号：US20240148779A1
公开(公告)日：2024-05-09
申请号：US18484111
申请日：2023-10-10
Applicant: RENATUS INC.
Inventor： Hee Gon KIM
IPC: A61K31/724 , A61P25/28 , A61P29/00
CPC classification number: A61K31/724 , A61P25/28 , A61P29/00
Abstract: Provided is a method of i) preventing or reducing protein aggregation, ii) reducing protein deposition, iii) reducing cytotoxicity induced by protein aggregation or deposition or deposition, or iv) alleviating or reducing inflammation induced by protein aggregation or deposition in an individual, wherein the method comprises administering a therapeutically effective amount of a pharmaceutical composition including a gamma-cyclodextrin oligomer to the individual, thereby preventing or reducing protein aggregation, reducing protein deposition, reducing cytotoxicity induced by protein aggregation or deposition, or alleviating or reducing inflammation induced by protein aggregation or deposition in the individual diagnosed with, suspected to have, or at risk of developing proteinopathy.
-
公开(公告)号：US20240148745A1
公开(公告)日：2024-05-09
申请号：US18549457
申请日：2022-03-09
Applicant: FONDAZIONE CENTRO SAN RAFFAELE , INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE , ASSISTANCE PUBLIQUE HOPITAUX DE PARIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , SORBONNE UNIVERSITE , WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , HEINRICH HEINE UNIVERSITY DÜSSELDORF , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ , THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY , ISTITUTO SUPERIORE DI SANITÀ , CONSIGLIO NAZIONALE DELLE RICERCHE , IRBM S.P.A.
Inventor： Gianvito MARTINO , Paola PANINA , Brahim NAIT-OUMESMAR , Anne BARON-VAN EVERCOOREN , Tanja KUHLMANN , Sergio BARANZINI , Norbert GOEBELS , Frauke ZIPP , Nicholas HANUSCHECK , Jack ANTEL , Cristina AGRESTI , Maria Pia ABBRACCHIO , Ivano EBERINI , Chiara PARRAVICINI , Stefania OLLA , Alberto BRESCIANI
IPC: A61K31/5377 , A61K31/405 , A61K31/4439 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/5025 , A61K31/55 , A61P25/28 , G01N33/50
CPC classification number: A61K31/5377 , A61K31/405 , A61K31/4439 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/5025 , A61K31/55 , A61P25/28 , G01N33/5058
Abstract: The present invention provides compounds able to induce neuroprotection of damaged neurons and boost the remyelination potential of oligodendrocytes. The compounds have been identified through methods of pharmacological screening of a small molecule library consisting of known pharmacologically active compounds and approved drugs. The screening method is also included in the invention.
-
公开(公告)号：US11970481B1
公开(公告)日：2024-04-30
申请号：US18481173
申请日：2023-10-04
Applicant: Nura Bio, Inc.
Inventor： Jennifer Aiden Kozak , Sean Pomeroy Brown , Christopher Michael Tegley , Alexander Wayne Schammel , Liusheng Zhu , Maximiliano De La Higuera Macias , Shilpa Sambashivan
IPC: C07D403/14 , A61P25/28 , C07D403/04
CPC classification number: C07D403/14 , A61P25/28 , C07D403/04
Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
-
-
-
-
-
-
-
-
-
Search Results
2108
records
(took 0.02 seconds)
